Novo Nordisk A/S

Global healthcare company with 95 years of innovation and leadership in diabetes care

Launch date

Jan 1923

Employees

Market cap

Net debt

-

Firm valuation

$281.5b (Public information from Aug 2022)

Bagsværd Capital Region of Denmark (HQ)

http://novonordisk.com

https://twitter.com/novonordisk https://www.facebook.com/novonordisk https://www.linkedin.com/company/novo-nordisk

Deals in current and previous year:

- view all undefined

Corporate Venture Fund: Novo Ventures, Novo Holdings

Revenues, earnings & profits over time

EUR	2016	2017	2018	2019	2020	2021	2022E
Revenues	-	14.9b	14.9b	16.3b	16.9b	18.8b	21.0b
% growth	-	-	-	9 %	4 %	11 %	12 %
EBITDA	-	7.0b	6.8b	7.8b	8.0b	8.6b	9.7b
% EBITDA margin	-	47 %	46 %	48 %	47 %	46 %	46 %
Profit	-	5.1b	5.2b	5.2b	5.6b	6.4b	6.7b
% profit margin	-	34 %	35 %	32 %	33 %	34 %	32 %
R&D budget	2.0b	1.9b	1.8b	1.7b	-	-	-
R&D % of revenue	-	13 %	12 %	11 %	-	-	-

Source: Company fillings or news article

Date	Investors	Amount	Round
-	5AM Ventures	N/A	- Not yet verified
May 1981	N/A	N/A	IPO Not yet verified
Dec 2018	N/A	$22m	Post IPO Equity Not yet verified
Total Funding		-

Tech stackLearn more about the technologies and tools that this company uses.

By Country

United States 5 Norway 1 Germany 1 France 1 Denmark 1 United Kingdom 1

By Industry

By Round

ACQUISITION 5 SERIES C 2 SERIES A 1 SERIES D 1

Osprey Pharmaceuticals USA

Xellia Pharmaceuticals

ACQUISITION by Novo Nordisk A/S May 2013

EMISPHERE TECHNOLOGIES

ACQUISITION by Novo Nordisk A/S Nov 2020

Dicerna Pharmaceuticals

ACQUISITION by Novo Nordisk A/S Nov 2021

Affimed Therapeutics

exited

exited

exited

ACQUISITION by Novo Nordisk A/S Jun 2020

ACQUISITION by Novo Nordisk A/S Aug 2018